ArticleCureus2024
Factors Associated With Rebleeding and Early Mortality Following Transcatheter Arterial Embolization for Spontaneous Muscle Hematoma: A Single-Center Experience Including the Period of the Coronavirus Disease Pandemic.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives We aim to investigate factors associated with rebleeding and mortality within one month of transcatheter arterial embolization (TAE) for spontaneous muscle hematoma (SMH) and the impact of the novel coronavirus disease 2019 (COVID-19). Methods This retrospective analysis included 33 patients who underwent TAE for SMH at a single center between 2012 and 2022. After 2020, eight of these patients had the COVID-19 infection. Patient characteristics, laboratory findings, embolic materials, and imaging findings were compared between the rebleeding and non-rebleeding groups, as well as between the early mortality and survival groups. Results Among all patients, 72.7% were on anticoagulant therapy before the onset of SMH. Of these, 27.2% required retreatment due to rebleeding. Patients who experienced rebleeding were more likely to have a platelet count below 50,000/µL, fibrinogen levels below 150 mg/dL, and an activated partial thromboplastin time (APTT) ratio above 2.5. Patients with SMH unrelated to anticoagulants had a higher rebleeding rate (56%), which may serve as a predictor of rebleeding. No significant difference in rebleeding rates was observed between patients with and without COVID-19 infection. Early mortality within one month of onset occurred in 24.2% of patients, with a higher prevalence among those with a history of malignancy. However, there was no increase in early mortality among patients who required retreatment for rebleeding. Conclusions Patients with a low platelet count, fibrinogen level, prolonged APTT, and non-anticoagulant-related SMH are at a high risk of rebleeding and require close monitoring. Severe comorbidities, including malignancies and COVID-19, can affect mortality rates. TAE remained effective even in cases of rebleeding. Advances in knowledge This study indicated non-anticoagulant-related SMH and hematological parameters as factors associated with rebleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.